Verzenio® – BiotechReality – Information Intelligence System for Biopharma

Eli Lilly and Company (NYSE: LLY) reported today that patients with high-risk early breast cancer who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), or both have demonstrated a statistically significant improvement in overall survival when using their medication Verzenio® (abemaciclib) in conjunction with endocrine therapy. The results are based on a seven-year analysis of the Phase 3 monarchE trial. In comparison to endocrine therapy alone, the study showed that Verzenio decreased the risk of death by 15.8% when used in conjunction with endocrine therapy. Since Verzenio is the first CDK4/6 inhibitor to demonstrate a notable overall survival benefit in this patient population, this represents a significant advancement. For patients, survival is what matters most — and abemaciclib plus endocrine therapy represents the first contemporary medicine in over two decades to deliver a clear improvement in overall survival in the adjuvant setting, These results represent an important step forward in the treatment of high-risk HR+, HER2− early breast cancer. Stephen Johnston Read More: Eli Lilly’s Oral Weight-Loss Drug Orforglipron Shows Promising Results in Phase 3 Trial 5,637 patients with HR+, HER2-, node-positive, high-risk early breast cancer were recruited for the global, randomised, open-label, Phase 3 monarchE trial. Overall survival (OS) was a crucial secondary endpoint, while invasive disease-free survival (IDFS) was the main goal of the trial. Among the seven-year analysis's main conclusions are: An ongoing improvement in distant relapse-free survival (DRFS) and invasive disease-free survival (IDFS). A 32% decrease in the incidence of metastatic illness in patients. The safety profile of Verzenio was consistent with previous findings, with no new safety concerns identified. The most prevalent cancer in women worldwide is breast cancer. Ninety percent of all breast cancers are thought to be discovered early. The HR+, HER2-subtype accounts for about 70% of all cases of breast cancer. With these encouraging outcomes, Lilly's Verzenio is well-positioned to have a big influence on how this prevalent type of breast cancer is treated. In-depth findings from the monarchE trial will be submitted for publication in a peer-reviewed journal and presented at a future medical conference. About Verzenio® (abemaciclib) Verzenio is a CDK4/6 inhibitor, a type of targeted therapy. It slows the growth and division of cancer cells by blocking two proteins, cyclin-dependent kinases 4 and 6. It is taken orally twice a day. Information: Eli Lilly and Company Last Modified:

Tag: Verzenio®

Lilly’s Verzenio® Shows Significant Survival Benefit in High-Risk Early Breast Cancer

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment